You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIndomethacin
Accession NumberDB00328  (APRD00109)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionIndomethacin is a non-steroidal antiinflammatory agent (NSAIA) with antiinflammatory, analgesic and antipyretic activity. Its pharmacological effect is thought to be mediated through inhibition of the enzyme cyclooxygenase (COX), the enzyme responsible for catalyzes the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway.
Structure
Thumb
Synonyms
{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid
1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
Aconip
Indocin
Indometacin
Indometacina
Indometacine
Indometacinum
Indomethacin
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ftp-indomethacinCapsule25 mgOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Ftp-indomethacinCapsule50 mgOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Indocid Cap 25mgCapsule25 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1965-12-311998-08-14Canada
Indocid Cap 50mgCapsule50 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1970-12-311998-08-14Canada
Indocid SR 75mgCapsule, extended release75 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1980-12-311999-08-06Canada
Indocid Sterile Oph Susp 1%Solution / drops10 mgOphthalmicMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1983-12-311999-08-06Canada
Indocid Sup 100mgSuppository100 mgRectalMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1971-12-312003-08-08Canada
Indocid Sup 50mgSuppository50 mgRectalMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1983-12-312003-08-08Canada
IndocinSuspension25 mg/5mLOralIroko Pharmaceuticals, LLC1985-10-10Not applicableUs
IndocollyreLiquid; Powder, for solution1 mgOphthalmicLaboratoire Chauvin S.A.1997-02-132001-01-19Canada
IndomethacinCapsule25 mg/1OralREMEDYREPACK INC.2013-01-21Not applicableUs
IndomethacinCapsule25 mg/1OralCardinal Health2010-10-29Not applicableUs
IndomethacinCapsule25 mg/1OralLiberty Pharmaceuticals, Inc.2013-04-23Not applicableUs
IndomethacinInjection, powder, lyophilized, for solution1 mg/mLIntravenousFresenius Kabi USA, LLC2010-03-19Not applicableUs
IndomethacinCapsule25 mg/1OralPd Rx Pharmaceuticals, Inc.2010-07-30Not applicableUs
IndomethacinCapsule25 mg/1OralREMEDYREPACK INC.2015-06-19Not applicableUs
IndomethacinCapsule50 mg/1OralPd Rx Pharmaceuticals, Inc.1984-04-20Not applicableUs
IndomethacinCapsule25 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
IndomethacinCapsule25 mg/1OralMylan Pharmaceuticals Inc.1984-04-20Not applicableUs
IndomethacinCapsule25 mg/1OralContract Pharmacy Services Pa2010-07-30Not applicableUs
IndomethacinCapsule25 mg/1OralMylan Institutional Inc.1998-09-10Not applicableUs
IndomethacinCapsule50 mg/1OralDIRECT RX2015-01-01Not applicableUs
IndomethacinCapsule25 mg/1OralCarilion Materials Management2010-07-10Not applicableUs
IndomethacinCapsule25 mg/1OralSTAT Rx USA LLC2010-09-15Not applicableUs
IndomethacinCapsule25 mg/1OralHeritage Pharmaceuticals Inc.2010-07-10Not applicableUs
IndomethacinCapsule25 mg/1OralClinical Solutions Wholesale, Llc2010-07-30Not applicableUs
IndomethacinCapsule25 mg/1OralPreferred Pharmaceuticals, Inc.2010-07-30Not applicableUs
IndomethacinCapsule25 mg/1OralPhysicians Total Care, Inc.2004-08-02Not applicableUs
IndomethacinCapsule25 mg/1OralProficient Rx LP2010-07-30Not applicableUs
IndomethacinCapsule50 mg/1OralProficient Rx LP2010-07-30Not applicableUs
IndomethacinCapsule25 mg/1OralREMEDYREPACK INC.2013-03-182016-10-22Us
IndomethacinCapsule50 mg/1OralHeritage Pharmaceuticals Inc.2010-07-30Not applicableUs
IndomethacinCapsule50 mg/1OralClinical Solutions Wholesale, Llc2010-07-30Not applicableUs
IndomethacinCapsule50 mg/1OralPreferred Pharmaceuticals, Inc.2010-07-30Not applicableUs
Novo-methacin - 100mg SupSuppository100 mgRectalNovopharm Limited1995-12-312005-08-10Canada
Novo-methacin - Sup 50mgSuppository50 mgRectalNovopharm Limited1995-12-312005-08-10Canada
Ntp-indomethacinCapsule25 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-indomethacinCapsule50 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-indo Cap 25mgCapsule25 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-indo Cap 50mgCapsule50 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Pro-indo 25 Cap 25mgCapsule25 mgOralPro Doc Limitee1985-12-312014-07-24Canada
Pro-indo 50 Cap 50mgCapsule50 mgOralPro Doc Limitee1985-12-312014-07-24Canada
Ratio-indomethacinSuppository100 mgRectalTeva Canada Limited1993-12-31Not applicableCanada
Ratio-indomethacinCapsule25 mgOralRatiopharm Inc Division Of Teva Canada Limited1997-01-212006-08-04Canada
Ratio-indomethacinCapsule50 mgOralRatiopharm Inc Division Of Teva Canada Limited1997-01-212006-08-04Canada
Ratio-indomethacinSuppository50 mgRectalRatiopharm Inc Division Of Teva Canada Limited1993-12-312006-08-04Canada
Rhodacine - Cap 25mgCapsule25 mgOralRhodiapharm Inc1996-11-282001-07-20Canada
Rhodacine - Cap 50mgCapsule50 mgOralRhodiapharm Inc1996-11-282001-07-20Canada
Rhodacine - Sup 100mgSuppository100 mgRectalRhoxalpharma Inc1995-12-312009-11-24Canada
Rhodacine - Sup 50mgSuppository50 mgRectalRhoxalpharma Inc1995-12-312009-11-24Canada
Sandoz IndomethacinSuppository50 mgRectalSandoz Canada Incorporated1997-11-17Not applicableCanada
Sandoz IndomethacinSuppository100 mgRectalSandoz Canada Incorporated1997-11-17Not applicableCanada
Teva-indomethacinCapsule25 mgOralTeva Canada Limited1980-12-31Not applicableCanada
Teva-indomethacinCapsule50 mgOralTeva Canada Limited1980-12-31Not applicableCanada
TivorbexCapsule20 mg/1OralIroko Pharmaceuticals, LLC2015-07-06Not applicableUs
TivorbexCapsule40 mg/1OralIroko Pharmaceuticals, LLC2015-07-06Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Indomethacin Cap 25mgCapsule25 mgOralApotex Inc1984-12-31Not applicableCanada
Apo Indomethacin Cap 50mgCapsule50 mgOralApotex Inc1984-12-31Not applicableCanada
IndocinSuppository50 mg/1RectalIroko Pharmaceuticals, LLC1992-08-31Not applicableUs
IndomethacinCapsule50 mg/1OralDIRECT RX2014-01-01Not applicableUs
IndomethacinCapsule25 mg/1OralDIRECT RX2014-01-01Not applicableUs
IndomethacinCapsule50 mg/1OralUnit Dose Services2011-11-01Not applicableUs
IndomethacinCapsule25 mg/1OralREMEDYREPACK INC.2014-08-26Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralAmerican Health Packaging2010-03-26Not applicableUs
IndomethacinCapsule25 mg/1OralREMEDYREPACK INC.2010-12-062016-10-13Us
IndomethacinCapsule, extended release75 mg/1OralBlenheim Pharmacal, Inc.2015-07-14Not applicableUs
IndomethacinCapsule25 mg/1OralTeva Pharmaceuticals USA Inc2007-12-14Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralEon Labs, Inc.1998-05-28Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralNu Care Pharmaceuticals, Inc.2010-12-06Not applicableUs
IndomethacinCapsule25 mg/1OralA S Medication Solutions Llc2011-11-01Not applicableUs
IndomethacinCapsule25 mg/1OralPd Rx Pharmaceuticals, Inc.2010-09-15Not applicableUs
IndomethacinCapsule25 mg/1OralHetero Drugs Ltd.,2011-04-12Not applicableUs
IndomethacinCapsule50 mg/1OralCamber Pharmaceuticals2011-11-01Not applicableUs
IndomethacinCapsule50 mg/1Oralbryant ranch prepack2010-07-30Not applicableUs
IndomethacinCapsule50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-04-20Not applicableUs
IndomethacinCapsule25 mg/1OralRebel Distributors Corp2010-12-22Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralREMEDYREPACK INC.2016-06-01Not applicableUs
IndomethacinCapsule50 mg/1OralPreferred Pharmaceuticals Inc.2016-11-16Not applicableUs
IndomethacinCapsule25 mg/1OralREMEDYREPACK INC.2013-09-26Not applicableUs
IndomethacinCapsule25 mg/1OralClinical Solutions Wholesale2007-12-14Not applicableUs
IndomethacinCapsule50 mg/1OralContract Pharmacy Services Pa2010-07-30Not applicableUs
IndomethacinCapsule50 mg/1OralRebel Distributors Corp2010-12-22Not applicableUs
IndomethacinCapsule50 mg/1OralBlenheim Pharmacal, Inc.2012-08-13Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralKvk Tech, Inc.2009-03-06Not applicableUs
IndomethacinCapsule50 mg/1OralPreferred Pharmaceuticals Inc.2016-08-05Not applicableUs
IndomethacinCapsule25 mg/1OralAv Pak2015-05-19Not applicableUs
IndomethacinCapsule50 mg/1OralREMEDYREPACK INC.2011-10-252016-12-02Us
IndomethacinCapsule, extended release75 mg/1OralA S Medication Solutions2009-03-06Not applicableUs
IndomethacinCapsule50 mg/1OralRed Pharm Drug, Inc.2008-08-01Not applicableUs
IndomethacinCapsule50 mg/1OralMylan Institutional Inc.1998-09-15Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralREMEDYREPACK INC.2015-10-28Not applicableUs
IndomethacinCapsule50 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2010-12-22Not applicableUs
IndomethacinCapsule50 mg/1OralTeva Pharmaceuticals USA Inc2007-12-14Not applicableUs
IndomethacinCapsule50 mg/1OralMylan Pharmaceuticals Inc.1984-04-20Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralCarilion Materials Management2009-03-06Not applicableUs
IndomethacinCapsule25 mg/1OralA S Medication Solutions Llc2011-11-01Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralPd Rx Pharmaceuticals, Inc.2012-07-27Not applicableUs
IndomethacinCapsule50 mg/1OralHetero Drugs Ltd.,2011-04-12Not applicableUs
IndomethacinCapsule25 mg/1Oralbryant ranch prepack2010-07-30Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-21Not applicableUs
IndomethacinCapsule50 mg/1OralRebel Distributors Corp1986-02-12Not applicableUs
IndomethacinCapsule50 mg/1OralREMEDYREPACK INC.2016-07-14Not applicableUs
IndomethacinInjection, powder, lyophilized, for solution1 mg/1IntravenousHospira, Inc.2016-11-30Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralA S Medication Solutions Llc2012-07-27Not applicableUs
IndomethacinCapsule50 mg/1OralClinical Solutions Wholesale2007-12-14Not applicableUs
IndomethacinCapsule25 mg/1OralRed Pharm Drug Inc.2010-07-16Not applicableUs
IndomethacinCapsule25 mg/1OralRebel Distributors Corp2010-07-30Not applicableUs
IndomethacinCapsule50 mg/1OralBlenheim Pharmacal, Inc.2010-11-08Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralCamber Pharmaceuticals, Inc.2012-09-28Not applicableUs
IndomethacinCapsule50 mg/1OralCadila Healthcare Limited2016-07-21Not applicableUs
IndomethacinCapsule50 mg/1OralAv Pak2015-05-20Not applicableUs
IndomethacinCapsule50 mg/1OralREMEDYREPACK INC.2011-09-082016-11-08Us
IndomethacinCapsule50 mg/1OralLake Erie Medical DBA Quality Care Products LLC1984-04-20Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralActavis Pharma, Inc.2013-12-17Not applicableUs
IndomethacinCapsule25 mg/1OralREMEDYREPACK INC.2013-03-26Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralDIRECT RX2015-01-01Not applicableUs
IndomethacinCapsule50 mg/1OralGlenmark Pharmaceuticals Inc., Usa2010-12-22Not applicableUs
IndomethacinCapsule25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-12-14Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralPaddock Laboratories, LLC2010-11-30Not applicableUs
IndomethacinCapsule25 mg/1OralSandoz Inc1987-04-292018-06-30Us
IndomethacinCapsule25 mg/1OralZydus Pharmaceuticals (USA) Inc.2016-07-21Not applicableUs
IndomethacinCapsule25 mg/1OralA S Medication Solutions Llc2010-12-22Not applicableUs
IndomethacinCapsule25 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2013-05-16Not applicableUs
IndomethacinCapsule50 mg/1OralMed Vantx, Inc.2007-12-14Not applicableUs
IndomethacinCapsule50 mg/1OralPhysicians Total Care, Inc.1999-07-27Not applicableUs
IndomethacinCapsule, extended release75 mg/1Oralbryant ranch prepack2010-12-06Not applicableUs
IndomethacinCapsule50 mg/1OralA S Medication Solutions2011-11-01Not applicableUs
IndomethacinCapsule50 mg/1OralA S Medication Solutions Llc2011-11-01Not applicableUs
IndomethacinCapsule50 mg/1OralREMEDYREPACK INC.2013-03-182016-11-01Us
IndomethacinCapsule25 mg/1OralNu Care Pharmaceuticals, Inc.2011-11-01Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralAv Pak2015-09-15Not applicableUs
IndomethacinCapsule50 mg/1OralRed Pharm Drug Inc.2007-04-01Not applicableUs
IndomethacinCapsule25 mg/1OralPd Rx Pharmaceuticals, Inc.2010-12-22Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralBlenheim Pharmacal, Inc.2015-06-01Not applicableUs
IndomethacinCapsule50 mg/1OralREMEDYREPACK INC.2014-05-07Not applicableUs
IndomethacinCapsule25 mg/1OralCadila Healthcare Limited2016-07-21Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralREMEDYREPACK INC.2012-03-012016-10-25Us
IndomethacinCapsule50 mg/1OralSTAT Rx USA LLC2010-07-16Not applicableUs
IndomethacinCapsule50 mg/1OralClinical Solutions Wholesale, Llc2010-12-22Not applicableUs
IndomethacinCapsule25 mg/1OralRed Pharm Drug, Inc.2010-12-22Not applicableUs
IndomethacinCapsule50 mg/1OralREMEDYREPACK INC.2013-05-13Not applicableUs
IndomethacinCapsule50 mg/1OralProficient Rx LP2011-11-01Not applicableUs
IndomethacinCapsule25 mg/1OralGlenmark Pharmaceuticals Inc., Usa2010-12-22Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralDispensing Solutions, Inc.2010-12-06Not applicableUs
IndomethacinSuppository50 mg/1RectalG & W LABORATORIES, INC.1992-08-31Not applicableUs
IndomethacinCapsule50 mg/1OralSandoz Inc1987-04-292017-09-30Us
IndomethacinCapsule50 mg/1OralZydus Pharmaceuticals (USA) Inc.2016-07-21Not applicableUs
IndomethacinCapsule25 mg/1OralA S Medication Solutions Llc2010-12-22Not applicableUs
IndomethacinCapsule50 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2013-05-16Not applicableUs
IndomethacinCapsule75 mg/1OralPhysicians Total Care, Inc.1995-04-26Not applicableUs
IndomethacinCapsule, extended release75 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-12-06Not applicableUs
IndomethacinCapsule25 mg/1OralA S Medication Solutions2010-12-22Not applicableUs
IndomethacinCapsule50 mg/1OralA S Medication Solutions Llc2011-11-01Not applicableUs
IndomethacinCapsule25 mg/1OralCamber Pharmaceuticals2011-11-01Not applicableUs
IndomethacinCapsule50 mg/1OralNu Care Pharmaceuticals, Inc.2011-11-01Not applicableUs
Indomethacin ERCapsule75 mg/1OralApotheca, Inc.2010-03-04Not applicableUs
Indomethacin ERCapsule75 mg/1OralApotheca, Inc.2006-05-02Not applicableUs
Indomethacin Extended-releaseCapsule75 mg/1OralKeltman Pharmaceuticals Inc.2006-01-09Not applicableUs
Indomethacin Extended-releaseCapsule75 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-10-05Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArthrexinAlphapharm
ElmetacinSankyo
IndaflexAndromaco
IndocidLundbeck
Indolar SRSandoz
IndomedGreater Pharma
IndoxenQuality Pharmaceutical
MetindolGlaxoSmithKline
MikametanMikasa Seiyaku
Nu-IndoNu-Pharm
ReumacideVitória
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Indomethacin sodium
74252-25-8
Thumb
  • InChI Key: UHYAQBLOGVNWNT-UHFFFAOYSA-M
  • Monoisotopic Mass: 433.090424
  • Average Mass: 433.82
DBSALT001435
Categories
UNIIXXE1CET956
CAS number53-86-1
WeightAverage: 357.788
Monoisotopic: 357.076785712
Chemical FormulaC19H16ClNO4
InChI KeyCGIGDMFJXJATDK-UHFFFAOYSA-N
InChI
InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
IUPAC Name
2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid
SMILES
COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
Pharmacology
IndicationFor moderate to severe rheumatoid arthritis including acute flares of chronic disease, ankylosing spondylitis, osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
Structured Indications
PharmacodynamicsIndomethacin, a NSAIA, with analgesic and antipyretic properties exerts its pharmacological effects by inhibiting the synthesis of prostaglandins involved in pain, fever, and inflammation. Indomethacin inhibits the catalytic activity of the COX enzymes, the enzymes responsible for catalyzing the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway. Indomethacin is known to inhibit two well-characterized isoforms of COX, COX-1 and COX-2, with greater selectivity for COX-1. COX-1 is a constitutively expressed enzyme that is involved in gastric mucosal protection, platelet and kidney function. It catalyzes the conversion of arachidonic acid to prostaglandin (PG) G2 and PGG2 to PGH2. COX-1 is involved in the synthesis pathways of PGE2, PGD2, PDF2a, PGI2 (also known as prostacyclin) and thromboxane A2 (TXA2). COX-2 is constitutively expressed and highly inducible by inflammatory stimuli. It is found in the central nervous system, kidneys, uterus and other organs. It also catalyzes the conversion of arachidonic acid to PGG2 and PGG2 to PGH2. In the COX-2-mediated pathway, PGH2 is subsequently converted to PGE2 and PGI2 (also known as prostacyclin). PGE2 is involved in mediating inflammation, pain and fever. Decreasing levels of PGE2 leads to decreased inflammation.
Mechanism of actionIndomethacin is a prostaglandin G/H synthase (also known as cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and -2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to a number of prostaglandins involved in fever, pain, swelling, inflammation, and platelet aggregation. Indomethacin antagonizes COX by binding to the upper portion of the active site, preventing its substrate, arachidonic acid, from entering the active site. Indomethacin, unlike other NSAIDs, also inhibits phospholipase A2, the enzyme responsible for releasing arachidonic acid from phospholipids. Indomethacin is more selective for COX-1 than COX-2, which accounts for its increased adverse gastric effects relative to other NSAIDs. COX-1 is required for maintaining the protective gastric mucosal layer. The analgesic, antipyretic and anti-inflammatory effects of indomethacin occur as a result of decreased prostaglandin synthesis. Its antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Phospholipase A2, membrane associatedProteinyes
inhibitor
HumanP14555 details
Prostaglandin reductase 2Proteinunknown
inhibitor
HumanQ8N8N7 details
Peroxisome proliferator-activated receptor gammaProteinunknown
activator
HumanP37231 details
Lactoylglutathione lyaseProteinunknown
inhibitor
HumanQ04760 details
Prostaglandin D2 receptor 2Proteinunknown
other/unknown
HumanQ9Y5Y4 details
Peroxisome proliferator-activated receptor alphaProteinunknown
agonist
HumanQ07869 details
Related Articles
AbsorptionBioavailability is approximately 100% following oral administration and 80–90% following rectal administration.
Volume of distributionNot Available
Protein binding97%
Metabolism

Hepatic.

SubstrateEnzymesProduct
Indomethacin
O-DesmethylindomethacinDetails
Indomethacin
Indomethacin acyl glucuronideDetails
Indomethacin
N-Deschlorobenzoyl indomethacinDetails
N-Deschlorobenzoyl indomethacin
Not Available
O-Desmethyl-N-deschlorobenzoyl indomethacinDetails
Route of eliminationIndomethacin is eliminated via renal excretion, metabolism, and biliary excretion.
Half life4.5 hours
ClearanceNot Available
ToxicityThe following symptoms may be observed following overdosage: nausea, vomiting, intense headache, dizziness, mental confusion, disorientation, or lethargy. There have been reports of paresthesias, numbness, and convulsions. The oral LD50 of indomethacin in mice and rats (based on 14 day mortality response) was 50 and 12 mg/kg, respectively.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Indomethacin Action PathwayDrug actionSMP00104
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Indomethacin is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Indomethacin is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Indomethacin is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Indomethacin is combined with 5-androstenedione.Experimental, Illicit
AbciximabIndomethacin may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Indomethacin can be decreased when combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Indomethacin.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Aceclofenac.Approved
AcenocoumarolIndomethacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Indomethacin.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Indomethacin.Approved, Vet Approved
AclarubicinIndomethacin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Indomethacin.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Indomethacin.Approved
AlbendazoleThe serum concentration of Indomethacin can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Alclometasone.Approved
AldosteroneThe serum concentration of Indomethacin can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Indomethacin can be increased when it is combined with Alectinib.Approved
Alendronic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Alendronic acid.Approved
AlfentanilThe serum concentration of Indomethacin can be increased when it is combined with Alfentanil.Approved, Illicit
AliskirenIndomethacin may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Indomethacin.Approved, Investigational
AlprenololIndomethacin may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Indomethacin.Approved, Investigational
AmantadineThe serum concentration of Indomethacin can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Indomethacin.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Amcinonide.Approved
AmikacinIndomethacin may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideIndomethacin may decrease the antihypertensive activities of Amiloride.Approved
Aminohippuric acidThe serum concentration of Indomethacin can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Indomethacin can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Indomethacin.Approved
AmlodipineThe serum concentration of Indomethacin can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Indomethacin can be decreased when it is combined with Amprenavir.Approved
AmrubicinIndomethacin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AmsacrineThe serum concentration of Indomethacin can be increased when it is combined with Amsacrine.Approved
AncrodIndomethacin may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Indomethacin is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Anisodamine.Investigational
annamycinIndomethacin may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Antipyrine.Approved
Antithrombin III humanIndomethacin may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Indomethacin may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Indomethacin.Approved
ApramycinIndomethacin may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Indomethacin is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Indomethacin can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinIndomethacin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinIndomethacin may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanIndomethacin may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArmodafinilThe metabolism of Indomethacin can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololIndomethacin may decrease the antihypertensive activities of Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Indomethacin.Approved, Investigational
AstemizoleThe serum concentration of Indomethacin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Indomethacin.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Indomethacin.Approved
AtorvastatinThe serum concentration of Indomethacin can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Indomethacin.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Azapropazone.Withdrawn
AzelastineThe serum concentration of Indomethacin can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indomethacin.Approved
AzithromycinThe serum concentration of Indomethacin can be increased when it is combined with Azithromycin.Approved
BalsalazideIndomethacin may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminIndomethacin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololIndomethacin may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Indomethacin.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Indomethacin.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Benoxaprofen.Withdrawn
BenzocaineThe serum concentration of Indomethacin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Indomethacin can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Indomethacin.Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Indomethacin.Approved, Vet Approved
BetaxololIndomethacin may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Betulinic Acid.Investigational
BevantololIndomethacin may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Indomethacin.Approved, Investigational
BiperidenThe serum concentration of Indomethacin can be increased when it is combined with Biperiden.Approved
BisoprololIndomethacin may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinIndomethacin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Indomethacin.Approved
BopindololIndomethacin may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Indomethacin can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Indomethacin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Indomethacin.Approved
BromfenacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Indomethacin.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Bucillamine.Investigational
BucindololIndomethacin may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Budesonide.Approved
BufuralolIndomethacin may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideIndomethacin may decrease the diuretic activities of Bumetanide.Approved
BupranololIndomethacin may decrease the antihypertensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Indomethacin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Indomethacin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Indomethacin.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Indomethacin.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Indomethacin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Indomethacin.Approved
CandesartanThe serum concentration of Indomethacin can be increased when it is combined with Candesartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Indomethacin.Experimental
CapecitabineThe metabolism of Indomethacin can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Indomethacin can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Indomethacin can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Indomethacin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Indomethacin.Approved
CarprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololIndomethacin may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolThe serum concentration of Indomethacin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Indomethacin can be increased when it is combined with Caspofungin.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Celecoxib.Approved, Investigational
CeliprololIndomethacin may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Indomethacin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Indomethacin.Withdrawn
CertoparinIndomethacin may increase the anticoagulant activities of Certoparin.Approved
ChloramphenicolThe metabolism of Indomethacin can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Indomethacin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indomethacin.Approved, Vet Approved
ChlorpromazineThe serum concentration of Indomethacin can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Indomethacin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Indomethacin can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Indomethacin.Approved
CholecalciferolThe metabolism of Indomethacin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Indomethacin can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Indomethacin can be decreased when it is combined with Cholic Acid.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ciclesonide.Approved, Investigational
CilazaprilThe serum concentration of Indomethacin can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Indomethacin.Approved
CimetidineThe serum concentration of Indomethacin can be decreased when it is combined with Cimetidine.Approved
CinoxacinIndomethacin may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinIndomethacin may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Indomethacin.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Indomethacin.Approved
Citric AcidIndomethacin may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Indomethacin can be increased when it is combined with Clarithromycin.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Indomethacin.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clodronate.Approved, Investigational, Vet Approved
ClofazimineThe serum concentration of Indomethacin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Indomethacin.Approved, Investigational
ClomipramineThe serum concentration of Indomethacin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Indomethacin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Indomethacin.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Indomethacin.Vet Approved
ClotrimazoleThe serum concentration of Indomethacin can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Indomethacin.Approved
CobicistatThe serum concentration of Indomethacin can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Indomethacin.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Indomethacin.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Indomethacin can be increased when it is combined with Colforsin.Experimental
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Indomethacin.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Cortisone acetate.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Indomethacin.Approved
CurcuminThe risk or severity of adverse effects can be increased when Indomethacin is combined with Curcumin.Investigational
CyclophosphamideThe serum concentration of Indomethacin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineIndomethacin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe serum concentration of Indomethacin can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Indomethacin is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Indomethacin.Approved
DabrafenibThe serum concentration of Indomethacin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Indomethacin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Indomethacin can be increased when it is combined with Dactinomycin.Approved
DalteparinIndomethacin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidIndomethacin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Indomethacin.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Indomethacin.Approved, Investigational
DaunorubicinIndomethacin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Indomethacin.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Indomethacin is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Indomethacin is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Indomethacin can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Indomethacin can be increased when it is combined with Desipramine.Approved
DesirudinIndomethacin may increase the anticoagulant activities of Desirudin.Approved
DesloratadineThe serum concentration of Indomethacin can be increased when it is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe serum concentration of Indomethacin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Indomethacin.Approved
DextranIndomethacin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Indomethacin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Indomethacin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Indomethacin may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of Indomethacin can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Indomethacin.Approved, Illicit, Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Indomethacin.Approved, Vet Approved
DiclofenacThe serum concentration of Indomethacin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolIndomethacin may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Indomethacin.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Indomethacin is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Indomethacin.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Indomethacin.Approved
DihydroergotamineThe serum concentration of Indomethacin can be increased when it is combined with Dihydroergotamine.Approved
DihydrostreptomycinIndomethacin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Indomethacin.Illicit
DiltiazemThe serum concentration of Indomethacin can be increased when it is combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Indomethacin.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Indomethacin.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Indomethacin.Approved
DipyridamoleThe serum concentration of Indomethacin can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Indomethacin.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Indomethacin.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Indomethacin can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Indomethacin can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Indomethacin.Approved, Investigational
DoxorubicinIndomethacin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DronabinolThe serum concentration of Indomethacin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Indomethacin can be increased when it is combined with Dronedarone.Approved
DrospirenoneIndomethacin may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Indomethacin is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ebselen.Investigational
Edetic AcidIndomethacin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Indomethacin.Approved
EfavirenzThe metabolism of Indomethacin can be decreased when combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Indomethacin can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Indomethacin.Approved, Investigational
EnalaprilThe serum concentration of Indomethacin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Indomethacin.Approved
EnoxacinIndomethacin may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinIndomethacin may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Indomethacin can be increased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Indomethacin.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Indomethacin is combined with Epirizole.Approved
EpirubicinIndomethacin may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneIndomethacin may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Indomethacin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Indomethacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Indomethacin is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Equilin.Approved
ErgonovineThe serum concentration of Indomethacin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Indomethacin can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Indomethacin.Approved, Investigational
ErythromycinThe serum concentration of Indomethacin can be decreased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe metabolism of Indomethacin can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololIndomethacin may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Indomethacin can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Indomethacin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Indomethacin can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Indomethacin can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Indomethacin can be decreased when it is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Estrone sulfate.Approved
Etacrynic acidIndomethacin may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Indomethacin.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Indomethacin.Approved
Ethyl biscoumacetateIndomethacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etofenamate.Approved
EtoposideThe serum concentration of Indomethacin can be increased when it is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Indomethacin can be increased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Indomethacin is combined with Evening primrose oil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Indomethacin.Approved
exisulindThe risk or severity of adverse effects can be increased when Indomethacin is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Indomethacin.Approved
FelodipineThe serum concentration of Indomethacin can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Indomethacin.Vet Approved
FentanylThe serum concentration of Indomethacin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Indomethacin.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Indomethacin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Indomethacin.Approved
FleroxacinIndomethacin may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Indomethacin.Approved, Withdrawn
FloxuridineThe metabolism of Indomethacin can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Indomethacin is combined with fluasterone.Investigational
FluconazoleThe metabolism of Indomethacin can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fludrocortisone.Approved
FluindioneIndomethacin may increase the anticoagulant activities of Fluindione.Investigational
FlumequineIndomethacin may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Indomethacin can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Indomethacin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Indomethacin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Indomethacin can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Indomethacin.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flurandrenolide.Approved
FlurazepamThe serum concentration of Indomethacin can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Indomethacin.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Indomethacin can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Indomethacin can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Indomethacin.Approved, Nutraceutical, Vet Approved
FondaparinuxIndomethacin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumIndomethacin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Indomethacin.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Indomethacin.Approved
FosphenytoinThe metabolism of Indomethacin can be increased when combined with Fosphenytoin.Approved
FramycetinIndomethacin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideIndomethacin may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateIndomethacin may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinIndomethacin may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinIndomethacin may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Indomethacin.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Indomethacin.Approved
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Indomethacin.Approved, Withdrawn
GemfibrozilThe metabolism of Indomethacin can be decreased when combined with Gemfibrozil.Approved
GemifloxacinIndomethacin may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinIndomethacin may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinThe serum concentration of Indomethacin can be increased when it is combined with Genistein.Investigational
GentamicinIndomethacin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AIndomethacin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Glucagon recombinantThe therapeutic efficacy of Glucagon recombinant can be decreased when used in combination with Indomethacin.Approved
GlyburideThe serum concentration of Indomethacin can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Indomethacin can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Indomethacin can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Indomethacin.Approved
GrepafloxacinIndomethacin may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Indomethacin is combined with HE3286.Investigational
HeparinIndomethacin may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Higenamine.Investigational
HirulogIndomethacin may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Indomethacin is combined with HMPL-004.Investigational
HydralazineIndomethacin may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Indomethacin.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Indomethacin.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Indomethacin.Approved
Hygromycin BIndomethacin may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ibandronate.Approved, Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Indomethacin.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Indomethacin is combined with Icatibant.Approved
IdarubicinIndomethacin may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Indomethacin.Approved
idraparinuxIndomethacin may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Indomethacin.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Indomethacin.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Indomethacin.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Indomethacin.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Indomethacin.Approved
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Indomethacin.Approved
IndenololIndomethacin may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indomethacin can be decreased when it is combined with Indinavir.Approved
IndoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Indoprofen.Withdrawn
INNO-206Indomethacin may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Indomethacin can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Indomethacin.Approved, Investigational
IsavuconazoniumThe serum concentration of Indomethacin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Indomethacin can be decreased when combined with Isoniazid.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Indomethacin is combined with Istaroxime.Investigational
ItraconazoleThe serum concentration of Indomethacin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Indomethacin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Indomethacin.Approved, Vet Approved
KanamycinIndomethacin may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Kebuzone.Experimental
KetamineThe serum concentration of Indomethacin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Indomethacin.Approved
KetoconazoleThe serum concentration of Indomethacin can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Indomethacin.Approved
LabetalolIndomethacin may decrease the antihypertensive activities of Labetalol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Indomethacin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Indomethacin.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Indomethacin.Approved, Investigational
LapatinibThe serum concentration of Indomethacin can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Indomethacin.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Indomethacin.Approved
LeflunomideThe metabolism of Indomethacin can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Indomethacin.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Indomethacin.Approved
LepirudinIndomethacin may increase the anticoagulant activities of Lepirudin.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Indomethacin.Approved, Investigational
LevobunololIndomethacin may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinIndomethacin may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Indomethacin.Approved
LevothyroxineThe serum concentration of Indomethacin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Indomethacin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Indomethacin.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Indomethacin.Approved
LiothyronineThe serum concentration of Indomethacin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Indomethacin can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Indomethacin can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Indomethacin.Approved
LomefloxacinIndomethacin may increase the neuroexcitatory activities of Lomefloxacin.Approved
LomitapideThe serum concentration of Indomethacin can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Indomethacin.Approved
LopinavirThe metabolism of Indomethacin can be increased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Indomethacin can be increased when it is combined with Loratadine.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lornoxicam.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Indomethacin.Approved
LovastatinThe serum concentration of Indomethacin can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Indomethacin.Approved, Investigational
LuliconazoleThe serum concentration of Indomethacin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Indomethacin can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Indomethacin.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Magnesium salicylate.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Indomethacin.Approved, Investigational
MaprotilineThe serum concentration of Indomethacin can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Indomethacin.Approved
ME-609The risk or severity of adverse effects can be increased when Indomethacin is combined with ME-609.Investigational
MebendazoleThe serum concentration of Indomethacin can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mefenamic acid.Approved
MefloquineThe serum concentration of Indomethacin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Indomethacin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Meloxicam.Approved, Vet Approved
MeprobamateThe serum concentration of Indomethacin can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineIndomethacin may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Indomethacin is combined with Metamizole.Withdrawn
MethadoneThe serum concentration of Indomethacin can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Indomethacin.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Indomethacin.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Indomethacin.Approved, Vet Approved
MetipranololIndomethacin may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Indomethacin.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Indomethacin.Approved, Investigational
MetrizamideIndomethacin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MibefradilThe serum concentration of Indomethacin can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Indomethacin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Indomethacin can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Indomethacin can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Indomethacin.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Indomethacin.Approved
MitomycinThe serum concentration of Indomethacin can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Indomethacin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Indomethacin can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Indomethacin can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Indomethacin.Approved
MometasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Indomethacin.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Indomethacin.Approved, Investigational
MoxifloxacinIndomethacin may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Indomethacin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Indomethacin.Approved
NadroparinIndomethacin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatIndomethacin may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Naftifine.Approved
Nalidixic AcidIndomethacin may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Indomethacin.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Indomethacin.Approved, Vet Approved
NaltrexoneThe serum concentration of Indomethacin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Naproxen.Approved, Vet Approved
NaringeninThe serum concentration of Indomethacin can be increased when it is combined with Naringenin.Experimental
NCX 1022The risk or severity of adverse effects can be increased when Indomethacin is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Indomethacin is combined with NCX 4016.Investigational
NeamineIndomethacin may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe serum concentration of Indomethacin can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Indomethacin can be decreased when it is combined with Nelfinavir.Approved
NemonoxacinIndomethacin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinIndomethacin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NeostigmineThe serum concentration of Indomethacin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nepafenac.Approved
NetilmicinIndomethacin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NicardipineThe metabolism of Indomethacin can be decreased when combined with Nicardipine.Approved
NifedipineThe serum concentration of Indomethacin can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Niflumic Acid.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Indomethacin.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nimesulide.Approved, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Indomethacin.Approved
NisoldipineThe serum concentration of Indomethacin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Indomethacin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Indomethacin can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nitroaspirin.Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Indomethacin.Approved
NorethisteroneThe serum concentration of Indomethacin can be decreased when it is combined with Norethisterone.Approved
NorfloxacinIndomethacin may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinIndomethacin may increase the neuroexcitatory activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Indomethacin.Approved, Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indomethacin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Olopatadine.Approved
OlsalazineIndomethacin may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Indomethacin.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Indomethacin.Approved
OmeprazoleThe serum concentration of Indomethacin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Indomethacin.Approved
OtamixabanIndomethacin may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oxaprozin.Approved
OxprenololIndomethacin may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oxyphenbutazone.Withdrawn
P-NitrophenolThe serum concentration of Indomethacin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Indomethacin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of Indomethacin can be increased when it is combined with Palmitic Acid.Experimental
PamidronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pamidronate.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Indomethacin.Approved, Investigational
PantoprazoleThe serum concentration of Indomethacin can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Parecoxib.Approved
ParomomycinIndomethacin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineThe serum concentration of Indomethacin can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Indomethacin.Approved
PazufloxacinIndomethacin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinIndomethacin may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololIndomethacin may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateIndomethacin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe serum concentration of Indomethacin can be increased when it is combined with Perindopril.Approved
PhenindioneIndomethacin may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Indomethacin can be increased when combined with Phenobarbital.Approved
PhenprocoumonIndomethacin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Indomethacin can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Indomethacin can be increased when it is combined with Pimozide.Approved
PindololIndomethacin may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinIndomethacin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideIndomethacin may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Piroxicam.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Indomethacin.Approved
Platelet Activating FactorThe serum concentration of Indomethacin can be decreased when it is combined with Platelet Activating Factor.Experimental
PlicamycinIndomethacin may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Indomethacin.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Indomethacin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Indomethacin.Approved
PosaconazoleThe serum concentration of Indomethacin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololIndomethacin may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Indomethacin.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Prasterone.Approved, Nutraceutical
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Indomethacin.Approved
PrazosinThe serum concentration of Indomethacin can be increased when it is combined with Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Prednicarbate.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Indomethacin.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Indomethacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Indomethacin can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Indomethacin can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Indomethacin can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Indomethacin can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Propacetamol.Approved
PropafenoneThe serum concentration of Indomethacin can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Indomethacin.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Indomethacin.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Indomethacin.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Indomethacin.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Indomethacin.Vet Approved
Protein CIndomethacin may increase the anticoagulant activities of Protein C.Approved
Protein S humanIndomethacin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeIndomethacin may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Indomethacin can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Indomethacin.Approved
PrulifloxacinIndomethacin may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Indomethacin is combined with PTC299.Investigational
PuromycinIndomethacin may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Indomethacin can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuercetinThe serum concentration of Indomethacin can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Indomethacin.Approved
QuinacrineThe serum concentration of Indomethacin can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Indomethacin.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Indomethacin.Approved
QuinidineThe serum concentration of Indomethacin can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Indomethacin can be increased when it is combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Indomethacin.Approved
RanitidineThe serum concentration of Indomethacin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Indomethacin.Approved, Investigational
ReboxetineThe serum concentration of Indomethacin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Indomethacin can be increased when it is combined with Regorafenib.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Indomethacin.Approved
ReserpineThe serum concentration of Indomethacin can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Resveratrol.Experimental, Investigational
ReviparinIndomethacin may increase the anticoagulant activities of Reviparin.Approved
RibostamycinIndomethacin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Indomethacin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Indomethacin can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Indomethacin.Approved, Investigational
RilpivirineThe serum concentration of Indomethacin can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Risedronate.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Indomethacin.Approved, Investigational
RitonavirThe serum concentration of Indomethacin can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Indomethacin.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Rofecoxib.Investigational, Withdrawn
RolapitantThe serum concentration of Indomethacin can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Indomethacin.Approved, Investigational
RosoxacinIndomethacin may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Indomethacin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylamide.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Indomethacin.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Indomethacin.Experimental
SaquinavirThe serum concentration of Indomethacin can be decreased when it is combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Indomethacin.Investigational
ScopolamineThe serum concentration of Indomethacin can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Indomethacin can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Indomethacin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Indomethacin.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Indomethacin is combined with Seratrodast.Approved, Investigational
SertralineThe serum concentration of Indomethacin can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Indomethacin can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Indomethacin.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Indomethacin.Approved
SimvastatinThe serum concentration of Indomethacin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Indomethacin can be decreased when it is combined with Sirolimus.Approved, Investigational
SisomicinIndomethacin may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Indomethacin.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Indomethacin.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Indomethacin.Approved, Investigational
SotalolIndomethacin may decrease the antihypertensive activities of Sotalol.Approved
SP1049CIndomethacin may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinIndomethacin may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinIndomethacin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Indomethacin.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Indomethacin.Approved
SpironolactoneThe serum concentration of Indomethacin can be increased when it is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Indomethacin is combined with SRT501.Investigational
St. John's WortThe serum concentration of Indomethacin can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Indomethacin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe metabolism of Indomethacin can be decreased when combined with Stiripentol.Approved
StreptomycinIndomethacin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinIndomethacin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Indomethacin can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Indomethacin can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineIndomethacin may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfinpyrazoneThe serum concentration of Indomethacin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Indomethacin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Indomethacin is combined with Sulindac.Approved
SulodexideIndomethacin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Indomethacin.Investigational
SumatriptanThe serum concentration of Indomethacin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Indomethacin can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Suprofen.Approved, Withdrawn
TacrineThe serum concentration of Indomethacin can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Indomethacin can be decreased when it is combined with Tacrolimus.Approved, Investigational
TacrolimusIndomethacin may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Indomethacin.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Indomethacin.Approved
TamoxifenThe serum concentration of Indomethacin can be decreased when it is combined with Tamoxifen.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Indomethacin.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Indomethacin.Experimental
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Indomethacin is combined with Technetium Tc-99m Medronate.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Indomethacin.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Indomethacin.Approved
TelmisartanThe serum concentration of Indomethacin can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinIndomethacin may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Indomethacin.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Indomethacin.Approved
TenofovirThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tepoxalin.Vet Approved
TerazosinThe serum concentration of Indomethacin can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Indomethacin can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe risk or severity of adverse effects can be increased when Indomethacin is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Indomethacin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Indomethacin can be increased when it is combined with Testosterone.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Indomethacin.Approved
TiclopidineThe metabolism of Indomethacin can be decreased when combined with Ticlopidine.Approved
TiludronateThe serum concentration of Tiludronate can be increased when it is combined with Indomethacin.Approved, Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Indomethacin.Approved
TinoridineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tixocortol.Approved
TobramycinIndomethacin may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Indomethacin can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tolmetin.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Indomethacin.Approved
TopiramateThe metabolism of Indomethacin can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Indomethacin.Approved, Investigational
TorasemideIndomethacin may decrease the diuretic activities of Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Indomethacin.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Indomethacin.Approved
TranilastThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Indomethacin can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Indomethacin.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Indomethacin.Approved
TrazodoneThe serum concentration of Indomethacin can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Indomethacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Indomethacin is combined with Triamcinolone.Approved, Vet Approved
TriamtereneIndomethacin may increase the nephrotoxic activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Indomethacin.Approved, Vet Approved
TrifluoperazineThe serum concentration of Indomethacin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Indomethacin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Indomethacin can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Indomethacin can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Indomethacin is combined with Trisalicylate-choline.Approved
TroleandomycinThe serum concentration of Indomethacin can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinIndomethacin may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Indomethacin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Indomethacin.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Indomethacin.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Indomethacin is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Indomethacin can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinIndomethacin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Indomethacin can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Indomethacin.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Indomethacin.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Indomethacin.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Indomethacin.Approved
VerapamilThe serum concentration of Indomethacin can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Indomethacin can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Indomethacin.Approved, Investigational
VincristineThe serum concentration of Indomethacin can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Indomethacin can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Indomethacin.Approved
VoriconazoleThe metabolism of Indomethacin can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinIndomethacin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranIndomethacin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Indomethacin may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Indomethacin can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Indomethacin.Approved
ZileutonThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Indomethacin can be increased when it is combined with Zimelidine.Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zomepirac.Withdrawn
ZorubicinIndomethacin may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Avoid alcohol.
  • Take with food or antacids to reduce irritation.
References
Synthesis Reference

Hubertus L. Regtop, John R. Biffin, “Preparation of divalent metal salts of indomethacin.” U.S. Patent US5310936, issued November, 1917.

US5310936
General References
  1. Akbarpour F, Afrasiabi A, Vaziri ND: Severe hyperkalemia caused by indomethacin and potassium supplementation. South Med J. 1985 Jun;78(6):756-7. [PubMed:4002013 ]
  2. HART FD, BOARDMAN PL: INDOMETHACIN: A NEW NON-STEROID ANTI-INFLAMMATORY AGENT. Br Med J. 1963 Oct 19;2(5363):965-70. [PubMed:14056924 ]
  3. Lum GM, Aisenbrey GA, Dunn MJ, Berl T, Schrier RW, McDonald KM: In vivo effect of indomethacin to potentiate the renal medullary cyclic AMP response to vasopressin. J Clin Invest. 1977 Jan;59(1):8-13. [PubMed:187624 ]
  4. Phelan KM, Mosholder AD, Lu S: Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry. 2003 Nov;64(11):1328-34. [PubMed:14658947 ]
  5. Ragheb M: The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol. 1990 Oct;10(5):350-4. [PubMed:2258452 ]
External Links
ATC CodesS01CC02M02AA23M01AB01M01AB51C01EB03S01BC01
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (56.2 KB)
MSDSDownload (73.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9509
Blood Brain Barrier+0.9381
Caco-2 permeable+0.5857
P-glycoprotein substrateNon-substrate0.636
P-glycoprotein inhibitor INon-inhibitor0.9313
P-glycoprotein inhibitor IINon-inhibitor0.834
Renal organic cation transporterNon-inhibitor0.8334
CYP450 2C9 substrateNon-substrate0.712
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6436
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9302
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6978
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8728
BiodegradationNot ready biodegradable0.9743
Rat acute toxicity4.0722 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9818
hERG inhibition (predictor II)Non-inhibitor0.8306
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Iroko pharmaceuticals llc
  • Sandoz inc
  • Able laboratories inc
  • Avanthi inc
  • Inwood laboratories inc sub forest laboratories inc
  • Teva pharmaceuticals usa inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Halsey drug co inc
  • Heritage pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Parke davis div warner lambert co
  • Pioneer pharmaceuticals inc
  • Pliva inc
  • Roxane laboratories inc
  • Superpharm corp
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • App pharmaceuticals llc
  • G and w laboratories inc
  • Lundbeck inc
  • Bedford laboratories div ben venue laboratories inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral25 mg
CapsuleOral50 mg
Capsule, extended releaseOral75 mg
Solution / dropsOphthalmic10 mg
SuspensionOral25 mg/5mL
Liquid; powder, for solutionOphthalmic1 mg
CapsuleOral25 mg/1
CapsuleOral50 mg/1
Capsule, extended releaseOral75 mg/1
Injection, powder, lyophilized, for solutionIntravenous1 mg/1
Injection, powder, lyophilized, for solutionIntravenous1 mg/mL
SuppositoryRectal50 mg/1
CapsuleOral75 mg/1
SuppositoryRectal100 mg
SuppositoryRectal50 mg
CapsuleOral20 mg/1
CapsuleOral40 mg/1
Prices
Unit descriptionCostUnit
Indocin i.v. 1 mg vial642.6USD vial
Indomethacin 1 mg vial600.0USD vial
Indocin 50 mg suppository9.56USD suppository
Indomethacin CR 75 mg capsule3.12USD capsule
Indocin sr 75 mg capsule2.92USD capsule
Indomethacin powder2.57USD g
Ratio-Indomethacin 100 mg Suppository0.93USD suppository
Sandoz Indomethacin 100 mg Suppository0.93USD suppository
Sandoz Indomethacin 50 mg Suppository0.93USD suppository
Indomethacin 50 mg capsule0.65USD capsule
Indomethacin 25 mg capsule0.44USD capsule
Apo-Indomethacin 50 mg Capsule0.16USD capsule
Novo-Methacin 50 mg Capsule0.16USD capsule
Nu-Indo 50 mg Capsule0.16USD capsule
Apo-Indomethacin 25 mg Capsule0.09USD capsule
Novo-Methacin 25 mg Capsule0.09USD capsule
Nu-Indo 25 mg Capsule0.09USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8734847 No2010-04-232030-04-23Us
US8992982 No2010-04-232030-04-23Us
US9089471 No2010-04-232030-04-23Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point151U.S. Patent 3,161,654.
water solubility0.937 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.27HANSCH,C ET AL. (1995)
logS-4.62ADME Research, USCD
Caco2 permeability-4.69ADME Research, USCD
pKa4.5BUDAVARI,S ET AL. (1989)
Predicted Properties
PropertyValueSource
Water Solubility0.0024 mg/mLALOGPS
logP4.25ALOGPS
logP3.53ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)3.8ChemAxon
pKa (Strongest Basic)-2.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area68.53 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity94.81 m3·mol-1ChemAxon
Polarizability36.64 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.7 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-000i-1901000000-710010c41f0ded9b0f17View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzoylindoles. These are organic compounds containing an indole attached to a benzoyl moiety through the acyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassBenzoylindoles
Direct ParentBenzoylindoles
Alternative Parents
Substituents
  • Benzoylindole
  • Indole-3-acetic acid derivative
  • Indolyl carboxylic acid derivative
  • Indolecarboxylic acid derivative
  • Hydroxyindole
  • 4-halobenzoic acid or derivatives
  • Indole
  • Benzoic acid or derivatives
  • Benzoyl
  • Anisole
  • Halobenzene
  • Chlorobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Substituted pyrrole
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Pyrrole
  • Carboxamide group
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Bobadilla L RA, Perez-Alvarez V, Bracho Valdes I, Lopez-Sanchez P: Effect of pregnancy on the roles of nitric oxide and prostaglandins in 5-hydroxytryptamine-induced contractions in rat isolated thoracic and abdominal aorta. Clin Exp Pharmacol Physiol. 2005 Mar;32(3):202-9. [PubMed:15743404 ]
  2. Fornai M, Blandizzi C, Colucci R, Antonioli L, Bernardini N, Segnani C, Baragatti B, Barogi S, Berti P, Spisni R, Del Tacca M: Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut. 2005 May;54(5):608-16. [PubMed:15831902 ]
  3. Higuchi K, Tominaga K, Watanabe T, Uno H, Shiba M, Sasaki E, Tanigawa T, Takashima T, Hamaguchi M, Oshitani N, Matsumoto T, Iwanaga Y, Fukuda T, Fujiwara Y, Arakawa T: Indomethacin, but not Helicobacter pylori, inhibits adaptive relaxation in isolated guinea-pig stomach. Drugs Exp Clin Res. 2004;30(5-6):235-41. [PubMed:15700751 ]
  4. Kundu N, Walser TC, Ma X, Fulton AM: Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother. 2005 Oct;54(10):981-7. Epub 2005 May 13. [PubMed:15891886 ]
  5. Moth CW, Prusakiewicz JJ, Marnett LJ, Lybrand TP: Stereoselective binding of indomethacin ethanolamide derivatives to cyclooxygenase-1. J Med Chem. 2005 May 19;48(10):3613-20. [PubMed:15887968 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Armstrong PJ, Franklin DP, Carey DJ, Elmore JR: Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors. Ann Vasc Surg. 2005 Mar;19(2):248-57. [PubMed:15770365 ]
  2. Jerde TJ, Calamon-Dixon JL, Bjorling DE, Nakada SY: Celecoxib inhibits ureteral contractility and prostanoid release. Urology. 2005 Jan;65(1):185-90. [PubMed:15667901 ]
  3. Pilane CM, Labelle EF: Nitric oxide stimulated vascular smooth muscle cells undergo apoptosis induced in part by arachidonic acid derived eicosanoids. J Cell Physiol. 2005 Aug;204(2):423-7. [PubMed:15668944 ]
  4. Yokota A, Taniguchi M, Takahira Y, Tanaka A, Takeuchi K: Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats. J Pharmacol Exp Ther. 2005 Jul;314(1):302-9. Epub 2005 Apr 14. [PubMed:15831440 ]
  5. Zhang GS, Fu YB, Xia M: [Proliferation inhibition effect of indomethacin on CML cells associated with down-regulation of phosphorylated STAT1/STAT5 and inhibition of COX-2 expression]. Zhonghua Xue Ye Xue Za Zhi. 2004 Dec;25(12):732-5. [PubMed:15730717 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Phospholipid binding
Specific Function:
Thought to participate in the regulation of the phospholipid metabolism in biomembranes including eicosanoid biosynthesis. Catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides.
Gene Name:
PLA2G2A
Uniprot ID:
P14555
Molecular Weight:
16082.525 Da
References
  1. Geisslinger, G., & Lötsch, J. (2004). Non-steroidal anti-inflammatory drugs. In Encyclopedic reference of molecular pharmacology (pp. 667-671). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
15-oxoprostaglandin 13-oxidase activity
Specific Function:
Functions as 15-oxo-prostaglandin 13-reductase and acts on 15-keto-PGE1, 15-keto-PGE2, 15-keto-PGE1-alpha and 15-keto-PGE2-alpha with highest activity towards 15-keto-PGE2. Overexpression represses transcriptional activity of PPARG and inhibits adipocyte differentiation (By similarity).
Gene Name:
PTGR2
Uniprot ID:
Q8N8N7
Molecular Weight:
38498.74 Da
References
  1. Wu YH, Ko TP, Guo RT, Hu SM, Chuang LM, Wang AH: Structural basis for catalytic and inhibitory mechanisms of human prostaglandin reductase PTGR2. Structure. 2008 Nov 12;16(11):1714-23. doi: 10.1016/j.str.2008.09.007. [PubMed:19000823 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
activator
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation...
Gene Name:
PPARG
Uniprot ID:
P37231
Molecular Weight:
57619.58 Da
References
  1. Cho MC, Lee HS, Kim JH, Choe YK, Hong JT, Paik SG, Yoon DY: A simple ELISA for screening ligands of peroxisome proliferator-activated receptor-gamma. J Biochem Mol Biol. 2003 Mar 31;36(2):207-13. [PubMed:12689521 ]
  2. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997 Feb 7;272(6):3406-10. [PubMed:9013583 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, to S-lactoylglutathione. Involved in the regulation of TNF-induced transcriptional activity of NF-kappa-B. Required for normal osteoclastogenesis.
Gene Name:
GLO1
Uniprot ID:
Q04760
Molecular Weight:
20777.515 Da
References
  1. Sato S, Kwon Y, Kamisuki S, Srivastava N, Mao Q, Kawazoe Y, Uesugi M: Polyproline-rod approach to isolating protein targets of bioactive small molecules: isolation of a new target of indomethacin. J Am Chem Soc. 2007 Jan 31;129(4):873-80. [PubMed:17243824 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Prostaglandin j receptor activity
Specific Function:
Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is also implicated in mediating PTGDR2 effects. PGD2 induced receptor internalization. CRTH2 internalization can be regulated by diverse kinases such as, PKC, PKA, ADRBK1/GRK2, GPRK5/GRK5 and GRK6. Recepto...
Gene Name:
PTGDR2
Uniprot ID:
Q9Y5Y4
Molecular Weight:
43267.15 Da
References
  1. Hata AN, Lybrand TP, Breyer RM: Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2. J Biol Chem. 2005 Sep 16;280(37):32442-51. Epub 2005 Jul 19. [PubMed:16030019 ]
  2. Hata AN, Lybrand TP, Marnett LJ, Breyer RM: Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005 Mar;67(3):640-7. Epub 2004 Nov 24. [PubMed:15563582 ]
  3. Mathiesen JM, Ulven T, Martini L, Gerlach LO, Heinemann A, Kostenis E: Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005 Aug;68(2):393-402. Epub 2005 May 3. [PubMed:15870392 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fa...
Gene Name:
PPARA
Uniprot ID:
Q07869
Molecular Weight:
52224.595 Da
References
  1. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997 Feb 7;272(6):3406-10. [PubMed:9013583 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Triglyceride lipase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity,...
Gene Name:
CES1
Uniprot ID:
P23141
Molecular Weight:
62520.62 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Mano Y, Usui T, Kamimura H: Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96. Epub 2007 Jan 24. [PubMed:17245571 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Mano Y, Usui T, Kamimura H: In vitro inhibitory effects of non-steroidal antiinflammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 3beta-glucuronidation in human liver microsomes. Biopharm Drug Dispos. 2005 Jan;26(1):35-9. [PubMed:15593333 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Mano Y, Usui T, Kamimura H: Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96. Epub 2007 Jan 24. [PubMed:17245571 ]
  2. Mano Y, Usui T, Kamimura H: Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. Eur J Clin Pharmacol. 2007 Feb;63(2):211-6. Epub 2007 Jan 3. [PubMed:17200831 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P: Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7. [PubMed:11581266 ]
  2. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3. [PubMed:16460798 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412 ]
  2. Bai J, Lai L, Yeo HC, Goh BC, Tan TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57. [PubMed:14643890 ]
  3. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Hosokawa M, Schuetz JD, Sugiyama Y: Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos. 2009 Feb;37(2):315-21. doi: 10.1124/dmd.108.024018. Epub 2008 Nov 24. [PubMed:19029202 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Isoform 1: May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. Transports glutathione conjugates as leukotriene-c4 (LTC4) and N-ethylmaleimide S-glutathione (NEM-GS).Isoform 2: Inhibits TNF-alpha-mediated apoptosis through blocking one or more caspases.
Gene Name:
ABCC6
Uniprot ID:
O95255
Molecular Weight:
164904.81 Da
References
  1. Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A: Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002 May 10;277(19):16860-7. Epub 2002 Mar 5. [PubMed:11880368 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  2. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P: Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83. [PubMed:10917554 ]
  2. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674 ]
  3. Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A: Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J Biol Chem. 2002 May 10;277(19):16860-7. Epub 2002 Mar 5. [PubMed:11880368 ]
  4. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412 ]
  5. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3. [PubMed:16460798 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641 ]
  2. Kouzuki H, Suzuki H, Sugiyama Y: Pharmacokinetic study of the hepatobiliary transport of indomethacin. Pharm Res. 2000 Apr;17(4):432-8. [PubMed:10870987 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954 ]
  2. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456 ]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  4. Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999 Jan;276(1 Pt 2):F122-8. [PubMed:9887087 ]
  5. Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [PubMed:9950961 ]
  6. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364 ]
  7. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528 ]
  8. Uwai Y, Saito H, Inui K: Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000 Dec 1;409(1):31-6. [PubMed:11099697 ]
  9. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  2. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456 ]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  4. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099 ]
  5. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, Terasaki T: Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab. 2003 Apr;23(4):432-40. [PubMed:12679720 ]
  6. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Gedeon C, Behravan J, Koren G, Piquette-Miller M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102. Epub 2006 Feb 3. [PubMed:16460798 ]
  2. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926 ]
  3. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690 ]
  4. Kouzuki H, Suzuki H, Sugiyama Y: Pharmacokinetic study of the hepatobiliary transport of indomethacin. Pharm Res. 2000 Apr;17(4):432-8. [PubMed:10870987 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Purine nucleotide transmembrane transporter activity
Specific Function:
Participates in physiological processes involving bile acids, conjugated steroids and cyclic nucleotides. Enhances the cellular extrusion of cAMP and cGMP. Stimulates the ATP-dependent uptake of a range of physiological and synthetic lipophilic anions, including the glutathione S-conjugates leukotriene C4 and dinitrophenyl S-glutathione, steroid sulfates such as dehydroepiandrosterone 3-sulfate...
Gene Name:
ABCC11
Uniprot ID:
Q96J66
Molecular Weight:
154299.625 Da
References
  1. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD: Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol. 2005 Feb;67(2):545-57. Epub 2004 Nov 10. [PubMed:15537867 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, Tojo A, Cha SH, Sekine T, Sakthisekaran D, Endou H: Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):64-75. [PubMed:12063169 ]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  3. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Molecular Weight:
38118.64 Da
References
  1. Kouzuki H, Suzuki H, Sugiyama Y: Pharmacokinetic study of the hepatobiliary transport of indomethacin. Pharm Res. 2000 Apr;17(4):432-8. [PubMed:10870987 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Morita N, Kusuhara H, Sekine T, Endou H, Sugiyama Y: Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1179-84. [PubMed:11504818 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:40